Japan-based Takeda Pharmaceutical Company (NYSE: TAK, TYO: 4502) announced a partnership with US-based BridGene Biosciences, Inc. to discover new small molecule drug candidates for immunology and neurology using BridGene’s chemical proteomics platform, IMTAC. The collaboration aims to advance projects through hit finding and early lead development, with Takeda holding exclusive rights to develop and commercialize any resulting products.
Financial Terms
BridGene will receive an upfront payment and potential preclinical milestone payments totaling USD46 million. Additional clinical and commercial milestone payments could reach up to USD770 million if all milestones are achieved. BridGene is also eligible for tiered royalties on net sales of any products resulting from the partnership.
Collaboration Details
The partnership leverages BridGene’s IMTAC platform to target challenging proteins in immunology and neurology, aiming to identify novel drug candidates. Takeda’s exclusive rights cover global development and commercialization.-Fineline Info & Tech
Leave a Reply